Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sinohealth Holdings Limited
中康控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 2361)

ANNOUNCEMENT ON THE STATUS OF THE PUBLIC FLOAT

Reference is made to the announcement of the Company dated 5 December 2022 in relation to the adoption of the Share Award Scheme (the "**Announcement**"). Unless otherwise specified, capitalized terms used herein shall have the same meanings as defined in the Announcement.

The Board announces that, to the best of the knowledge, information and belief of the Board, as at the date of this announcement, the public float of the Company is approximately 16.45%, which has fallen below 25% of the total number of issued Shares of the Company required to be held by the public (the "**Minimum Prescribed Percentage**") as prescribed by Rule 8.08(1)(a) of the Listing Rules.

The table below sets out the shareholding structure of the Company as at the date of this announcement:

Shareholders	**Number of Shares**	**Approximate percentage of the total issued share capital of the Company**
WELLMARK LINK LIMITED	181,237,500	40.12%
WLF Investment Holdings Limited	20,250,000	4.48%
Rikan Industry Investment Limited Partnership	67,500,000	14.94%
Montesy Capital Holding Ltd	68,512,500	15.17%
Futu Trustee Limited — share awards not yet granted *(Note)*	39,958,477	8.84%
Public shareholders	74,311,523	16.45%
Total	451,770,000	100.00%

Note: Futu Trustee Limited is a professional trustee appointed under the Trust Deed to act as trustee of the Trust in respect of administration of the Share Award Scheme. For details, please refer to the Adoption of Share Award Scheme Announcement. The Company granted 4,472,523 Share Awards on 15 January 2026, the awarded Shares under which represent approximately 0.99% of the total issued Shares as at the date of this announcement. For details of the aforementioned grant of Share Awards, please refer to the announcement of the Company dated 15 January 2026.

PROPOSALS TO RESTORE PUBLIC FLOAT

To restore the public float of the Company, the Company will take the following measures to restore its public float as soon as possible:

(1) Taking into account the Company's strategic development and the performance completion of Eligible Participants, the Company expects to complete the grant of the share awards not yet granted within the next three years, subject to the Company's actual circumstances; and

(2) Having regard to its strategic development and prevailing market conditions, the Company does not rule out the possibility of conducting equity financing in the future to expand its share capital.

The Company will make further announcement(s) to provide shareholders of the Company with further details as and when appropriate and in compliance with the Listing Rules.

The Company will continue to publish announcement(s) on a regular basis to update its Shareholders and potential investors on the status of the public float and the measures that may be introduced by the Company to restore its public float as soon as practicable.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.

By Order of the Board
Sinohealth Holdings Limited
Wu Yushu
Chairman

Hong Kong, 21 January 2026

As at the date of this announcement, the executive Directors are Mr. Wu Yushu and Ms. Wang Lifang, the non-executive Director is Mr. Fu Haitao, and the independent non-executive Directors are Ms. Wang Danzhou, Ms. Chui Hoi Yam and Mr. Wei Bin.